133 related articles for article (PubMed ID: 28888979)
1. Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor.
Lundqvist J; Tringali C; Oskarsson A
J Steroid Biochem Mol Biol; 2017 Nov; 174():161-168. PubMed ID: 28888979
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs.
Oskarsson A; Spatafora C; Tringali C; Andersson ÅO
Prostate; 2014 Jun; 74(8):839-51. PubMed ID: 24610083
[TBL] [Abstract][Full Text] [Related]
3. Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actions.
Chakraborty S; Kumar A; Butt NA; Zhang L; Williams R; Rimando AM; Biswas PK; Levenson AS
Mol Biosyst; 2016 May; 12(5):1702-9. PubMed ID: 27063447
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
Robitaille CN; Rivest P; Sanderson JT
Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
[TBL] [Abstract][Full Text] [Related]
5. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells.
Wang TT; Schoene NW; Kim YS; Mizuno CS; Rimando AM
Mol Nutr Food Res; 2010 Mar; 54(3):335-44. PubMed ID: 20077416
[TBL] [Abstract][Full Text] [Related]
7. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP.
Montgomery BT; Young CY; Bilhartz DL; Andrews PE; Prescott JL; Thompson NF; Tindall DJ
Prostate; 1992; 21(1):63-73. PubMed ID: 1379363
[TBL] [Abstract][Full Text] [Related]
8. Steroid derivatives as pure antagonists of the androgen receptor.
Gauthier S; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
[TBL] [Abstract][Full Text] [Related]
9. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells.
Iguchi K; Toyama T; Ito T; Shakui T; Usui S; Oyama M; Iinuma M; Hirano K
J Androl; 2012; 33(6):1208-15. PubMed ID: 22700762
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
12. The antiandrogenic effect of finasteride against a mutant androgen receptor.
Wu Y; Chhipa RR; Zhang H; Ip C
Cancer Biol Ther; 2011 May; 11(10):902-9. PubMed ID: 21386657
[TBL] [Abstract][Full Text] [Related]
13. Anti-androgen receptor signaling and prostate cancer inhibitory effects of sucrose- and benzophenone-compounds.
Wang Z; Lee HJ; Wang L; Jiang C; Baek NI; Kim SH; Lü J
Pharm Res; 2009 May; 26(5):1140-8. PubMed ID: 19266268
[TBL] [Abstract][Full Text] [Related]
14. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines.
Hsieh TC; Wu JM
Exp Cell Res; 1999 May; 249(1):109-15. PubMed ID: 10328958
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor.
Harada N; Atarashi K; Murata Y; Yamaji R; Nakano Y; Inui H
J Steroid Biochem Mol Biol; 2011 Jan; 123(1-2):65-70. PubMed ID: 21073951
[TBL] [Abstract][Full Text] [Related]
16. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.
Tesei A; Leonetti C; Di Donato M; Gabucci E; Porru M; Varchi G; Guerrini A; Amadori D; Arienti C; Pignatta S; Paganelli G; Caraglia M; Castoria G; Zoli W
PLoS One; 2013; 8(5):e62657. PubMed ID: 23667504
[TBL] [Abstract][Full Text] [Related]
17. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
19. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
20. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
Ben Jemaa A; Sallami S; Céraline J; Oueslati R
Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
